Regular article
Gastrointestinal, hepatobiliary, and pancreatic pathology
Intestinal Microbiota Modulates Gluten-Induced Immunopathology in Humanized Mice

https://doi.org/10.1016/j.ajpath.2015.07.018Get rights and content
Under an Elsevier user license
open archive

Celiac disease (CD) is an immune-mediated enteropathy triggered by gluten in genetically susceptible individuals. The recent increase in CD incidence suggests that additional environmental factors, such as intestinal microbiota alterations, are involved in its pathogenesis. However, there is no direct evidence of modulation of gluten-induced immunopathology by the microbiota. We investigated whether specific microbiota compositions influence immune responses to gluten in mice expressing the human DQ8 gene, which confers moderate CD genetic susceptibility. Germ-free mice, clean specific-pathogen-free (SPF) mice colonized with a microbiota devoid of opportunistic pathogens and Proteobacteria, and conventional SPF mice that harbor a complex microbiota that includes opportunistic pathogens were used. Clean SPF mice had attenuated responses to gluten compared to germ-free and conventional SPF mice. Germ-free mice developed increased intraepithelial lymphocytes, markers of intraepithelial lymphocyte cytotoxicity, gliadin-specific antibodies, and a proinflammatory gliadin-specific T-cell response. Antibiotic treatment, leading to Proteobacteria expansion, further enhanced gluten-induced immunopathology in conventional SPF mice. Protection against gluten-induced immunopathology in clean SPF mice was reversed after supplementation with a member of the Proteobacteria phylum, an enteroadherent Escherichia coli isolated from a CD patient. The intestinal microbiota can both positively and negatively modulate gluten-induced immunopathology in mice. In subjects with moderate genetic susceptibility, intestinal microbiota changes may be a factor that increases CD risk.

Cited by (0)

See related Commentary on page 2864

Supported by Canadian Institutes of Health Research grant MOP#123282 (E.F.V.), partially by NIH grant R01 DK67189 (B.J.), The Stanley Medical Research Institute 08R-2061 (A.A. and S.H.), and MINECO grant AGL2011-25169 (Y.S.). H.J.G. and J.L.M. received a New Investigator Award from the Canadian Celiac Association, and M.M., Erwin Schrödinger Fellowship J 3418-B19 from the FWF Austrian Science Fund. E.F.V. and M.J. hold Canada Research Chairs.

H.J.G. and J.L.M. contributed equally to this work.

Disclosures: None declared.